Published in J Theor Biol on August 04, 2009
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS One (2010) 3.02
Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol (2010) 2.67
Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages. J Virol (2011) 2.55
Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. J Virol (2010) 2.39
Adaptation to the interferon-induced antiviral state by human and simian immunodeficiency viruses. J Virol (2013) 2.28
Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection. PLoS Pathog (2011) 2.13
Previously transmitted HIV-1 strains are preferentially selected during subsequent sexual transmissions. J Infect Dis (2012) 2.00
Designing a genome-based HIV incidence assay with high sensitivity and specificity. AIDS (2011) 1.88
A limited number of simian immunodeficiency virus (SIV) env variants are transmitted to rhesus macaques vaginally inoculated with SIVmac251. J Virol (2010) 1.84
Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository. AIDS (2014) 1.67
Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog (2012) 1.61
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
HIV transmission. Cold Spring Harb Perspect Med (2012) 1.52
Estimating time since infection in early homogeneous HIV-1 samples using a poisson model. BMC Bioinformatics (2010) 1.45
Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol (2011) 1.44
Demographic processes affect HIV-1 evolution in primary infection before the onset of selective processes. J Virol (2011) 1.41
Selective transmission of R5 HIV-1 variants: where is the gatekeeper? J Transl Med (2011) 1.36
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One (2011) 1.32
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog (2012) 1.30
Modeling the within-host dynamics of HIV infection. BMC Biol (2013) 1.29
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
Viral evolution and escape during acute HIV-1 infection. J Infect Dis (2010) 1.26
Identifying and characterizing recently transmitted viruses. Curr Opin HIV AIDS (2010) 1.19
Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology (2012) 1.18
Transmission of single and multiple viral variants in primary HIV-1 subtype C infection. PLoS One (2011) 1.16
Stochastic theory of early viral infection: continuous versus burst production of virions. PLoS Comput Biol (2011) 1.15
SIVmac251 is inefficiently transmitted to rhesus macaques by penile inoculation with a single SIVenv variant found in ramp-up phase plasma. AIDS Res Hum Retroviruses (2011) 1.13
Primary infection by a human immunodeficiency virus with atypical coreceptor tropism. J Virol (2011) 1.12
Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog (2015) 1.11
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
Impact of mutation type and amplicon characteristics on genetic diversity measures generated using a high-resolution melting diversity assay. J Mol Diagn (2012) 1.08
A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays. Virology (2009) 1.02
Genetic identity and biological phenotype of a transmitted/founder virus representative of nonpathogenic simian immunodeficiency virus infection in African green monkeys. J Virol (2010) 1.01
Neutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challenge. J Virol (2013) 1.01
Should we treat acute HIV infection? Curr HIV/AIDS Rep (2012) 1.00
Innate immunity in acute HIV-1 infection. Curr Opin HIV AIDS (2011) 0.95
A quantitative quasispecies theory-based model of virus escape mutation under immune selection. Proc Natl Acad Sci U S A (2012) 0.92
Using nonhuman primates to model HIV transmission. Curr Opin HIV AIDS (2013) 0.91
Activities of transmitted/founder and chronic clade B HIV-1 Vpu and a C-terminal polymorphism specifically affecting virion release. J Virol (2014) 0.91
Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathog (2016) 0.90
Evolution of drug-resistant viral populations during interruption of antiretroviral therapy. J Virol (2011) 0.89
Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. J Virol (2015) 0.86
Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. Open Forum Infect Dis (2014) 0.84
Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4. MBio (2015) 0.83
Vpu Exploits the Cross-Talk between BST2 and the ILT7 Receptor to Suppress Anti-HIV-1 Responses by Plasmacytoid Dendritic Cells. PLoS Pathog (2015) 0.83
Estimating the timing of mother-to-child transmission of the human immunodeficiency virus type 1 using a viral molecular evolution model. PLoS One (2014) 0.83
Sexually-transmitted/founder HIV-1 cannot be directly predicted from plasma or PBMC-derived viral quasispecies in the transmitting partner. PLoS One (2013) 0.83
Recombination-mediated escape from primary CD8+ T cells in acute HIV-1 infection. Retrovirology (2014) 0.82
Stochastic simulations suggest that HIV-1 survives close to its error threshold. PLoS Comput Biol (2012) 0.81
Modelling the course of an HIV infection: insights from ecology and evolution. Viruses (2012) 0.80
Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells. J Infect Dis (2013) 0.80
Performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay in Detecting "Recent" HIV Infection and Calculating Population Incidence. J Acquir Immune Defic Syndr (2016) 0.79
Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. J Virol (2016) 0.78
Characterizing HIV-1 Splicing Using Next Generation Sequencing. J Virol (2017) 0.77
SPMM: estimating infection duration of multivariant HIV-1 infections. Bioinformatics (2015) 0.77
HIV-1 Vpu utilizes both cullin-RING ligase (CRL) dependent and independent mechanisms to downmodulate host proteins. Retrovirology (2015) 0.77
The challenges of modelling antibody repertoire dynamics in HIV infection. Philos Trans R Soc Lond B Biol Sci (2015) 0.76
Simple mathematical models do not accurately predict early SIV dynamics. Viruses (2015) 0.76
Timing, adherence, resistance, and ... persistence? new insight into the mechanisms of failure of HIV type 1 postexposure prophylaxis. J Infect Dis (2013) 0.76
Investigating the Consequences of Interference between Multiple CD8+ T Cell Escape Mutations in Early HIV Infection. PLoS Comput Biol (2016) 0.76
Enhancing Virion Tethering by BST2 Sensitizes Productively and Latently HIV-infected T cells to ADCC Mediated by Broadly Neutralizing Antibodies. Sci Rep (2016) 0.76
Comprehensive Characterization of the Transmitted/Founder env Genes From a Single MSM Cohort in China. J Acquir Immune Defic Syndr (2015) 0.76
Modeling sequence evolution in HIV-1 infection with recombination. J Theor Biol (2013) 0.76
Molecular clock of HIV-1 envelope genes under early immune selection. Retrovirology (2016) 0.76
Survivors Remorse: antibody-mediated protection against HIV-1. Immunol Rev (2017) 0.75
Within-Epitope Interactions Can Bias CTL Escape Estimation in Early HIV Infection. Front Immunol (2017) 0.75
Understanding the effects of different HIV transmission models in individual-based microsimulation of HIV epidemic dynamics in people who inject drugs. Epidemiol Infect (2016) 0.75
Single-use, electricity-free amplification device for detection of HIV-1. J Virol Methods (2016) 0.75
Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes. Pathog Immun (2016) 0.75
Enhancement of viral escape in HIV-1 Nef by STEP vaccination. AIDS (2016) 0.75
The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards. Sci Rep (2017) 0.75
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
BEAST: Bayesian evolutionary analysis by sampling trees. BMC Evol Biol (2007) 74.13
Relaxed phylogenetics and dating with confidence. PLoS Biol (2006) 37.68
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Bayesian coalescent inference of past population dynamics from molecular sequences. Mol Biol Evol (2005) 18.57
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Pairwise comparisons of mitochondrial DNA sequences in stable and exponentially growing populations. Genetics (1991) 16.12
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
Timing the ancestor of the HIV-1 pandemic strains. Science (2000) 10.42
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science (1996) 7.73
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science (1992) 7.44
Maximum likelihood estimation of population growth rates based on the coalescent. Genetics (1998) 7.11
High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med (1991) 7.01
Selection for specific sequences in the external envelope protein of human immunodeficiency virus type 1 upon primary infection. J Virol (1993) 6.41
Clinical and epidemiologic features of primary HIV infection. Ann Intern Med (1996) 6.04
Estimating the pattern of nucleotide substitution. J Mol Evol (1994) 5.74
Retroviral restriction by APOBEC proteins. Nat Rev Immunol (2004) 5.00
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol (2009) 4.40
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Mapping trait loci by use of inferred ancestral recombination graphs. Am J Hum Genet (2006) 4.01
Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol (1997) 3.79
Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog (2005) 3.59
Viral dynamics of acute HIV-1 infection. J Exp Med (1999) 3.45
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
Characterization of human immunodeficiency virus type 1 (HIV-1) envelope variation and neutralizing antibody responses during transmission of HIV-1 subtype B. J Virol (2005) 2.83
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses (2002) 2.68
Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci U S A (1997) 2.64
Sexual transmission of HIV: infectiousness and prevention. AIDS (1999) 2.59
Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol (2004) 2.33
Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS (2000) 2.08
A robust measure of HIV-1 population turnover within chronically infected individuals. Mol Biol Evol (2004) 1.87
Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol (2009) 1.76
Viral dynamics in primary HIV-1 infection. Karolinska Institutet Primary HIV Infection Study Group. AIDS (2000) 1.75
Clinical picture of primary HIV infection presenting as a glandular-fever-like illness. BMJ (1988) 1.75
Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS (2002) 1.70
Forward mutation rate of human immunodeficiency virus type 1 in a T lymphoid cell line. AIDS Res Hum Retroviruses (1996) 1.65
Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol (2006) 1.59
A stochastic model for primary HIV infection: optimal timing of therapy. AIDS (1999) 1.53
Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A (2007) 1.48
Population genetic estimation of the loss of genetic diversity during horizontal transmission of HIV-1. BMC Evol Biol (2006) 1.27
Comparing likelihood and Bayesian coalescent estimation of population parameters. Genetics (2006) 1.25
Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog (2007) 1.22
Gene genealogy in a population of variable size. Heredity (Edinb) (1997) 1.19
Intermittent low-level viremia in very early primary HIV-1 infection. J Acquir Immune Defic Syndr (2005) 1.13
Two-sample tests for comparing intra-individual genetic sequence diversity between populations. Biometrics (2005) 1.10
Monte Carlo estimates of natural variation in HIV infection. J Theor Biol (2005) 1.06
Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious. J Virol (2004) 1.05
A stochastic model for early HIV-1 population dynamics. J Theor Biol (1998) 1.00
Stochastic modeling of the dynamics of CD4+ T-cell infection by HIV and some Monte Carlo studies. Math Biosci (1998) 0.98
A stochastic modeling of early HIV-1 population dynamics. Math Biosci (2001) 0.90
A new cell-based assay for measuring the forward mutation rate of HIV-1. J Virol Methods (2004) 0.85
Inheritance of defective extremities. Indian J Med Res (1977) 0.78
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA (2006) 17.93
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS (2003) 11.66
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA (2006) 7.49
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med (2004) 5.78
Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science (2008) 5.76
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA (2002) 5.56
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis (2009) 4.96
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med (2005) 4.83
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol (2002) 4.65
Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science (2007) 4.60
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A (2004) 4.37
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35
Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature (2010) 4.35
Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis (2005) 4.27
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature (2002) 4.20
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat Med (2006) 4.14